Biologics cut mortality risk in psoriasis regardless of treatment duration
In patients with moderate-to-severe psoriasis, biologic agents seem to reduce mortality risk regardless of treatment duration, a recent study has found. Methotrexate, on the other hand, only shows a similar efficacy when used for at least a year.
